Sigyn Therapeutics is advancing a blood purification therapy that could significantly enhance medical responses to emerging viral threats, targeting multiple mechanisms that contribute to life-threatening infections.
The company's innovative Sigyn Therapy aims to remove infectious viruses, bacterial toxins, inflammatory cytokines, and viral exosomes from the bloodstream before they can cause severe damage. With global viral outbreaks increasing—including mpox, Marburg virus, Ebola, H5N1 bird flu, and other emerging pathogens—the technology offers a potentially critical intervention strategy.
The therapy's key capabilities include clearing viral pathogens before they can replicate, reducing intestinal bacterial toxins that contribute to inflammatory responses, and dampening excessive cytokine production that can lead to organ failure. The device can process an entire bloodstream approximately 15 times during a four-hour treatment and is designed to be compatible with existing dialysis and continuous renal replacement therapy (CRRT) machines.
Initial clinical strategy focuses on end-stage renal disease patients with endotoxemia, with potential future applications in emergency and compassionate-use scenarios for viral outbreaks. The technology has demonstrated effectiveness in reducing circulating COVID-19 and other viruses in human blood plasma tests.
With global warming accelerating the spread of mosquito-borne viruses and new pathogens continually emerging, Sigyn Therapy represents a potential breakthrough in proactive infectious disease management, offering a versatile approach to mitigating viral threats before they can cause widespread harm.
